References
- Matthews DR, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/− oral agents in type 2 diabetes. Abstract 764. Diabetologia. 2012;55(Suppl 1):S314.
- Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208–219.
- Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–4021.
- Powell DR, Smith M, Doree D, et al. LX2761, an SGLT1 inhibitor restricted to the intestine, improves glycaemic control in mice. Diabetologia. 2013;56(Suppl 1):S399.
- Zhang L, Wang Y, Xu H, et al. Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Med Chem. 2014;10:304–317.
- Pafili K, Papanas N. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time? Expert Opin Pharmacother. 2015;16:453–456.
- Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother. 2014;15:1197–1201.
- Wilding JPH, Norwood P, T’Joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656–1662.
- Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–415.
- Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233.
- Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
- Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
- Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–938.
- Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
- Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–1478.
- Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–2224.
- Bailey CJ, Iqbal N, T’Joen C, et al. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14:951–959.
- U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes [cited 2015 Dec 18]. Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/2-2-2015-us-fda-approves-first-in-class-glyxambi-empagliflozin-linagliptin-tablets-adults-type-2-diabetes.html
- AstraZeneca receives complete response letter from US FDA for saxagliptin /dapagliflozin fixed-dose-combination [cited 2015 Dec 18]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-receives-complete-response-letter-from-us-16102015.html
- Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457–463.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
- Blonde L. State of diabetes care in the United States. Am J Manag Care. 2007;13 Suppl 2:S36–S40.
- Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs. 2007;8:285–292.
- World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59 (PDF). WHO Drug Information. 2008;22:66.
- American Medical Association. Statement on a nonproprietary name adopted by the USAN council: sergliflozin etabonate (PDF). Chicago (IL): American Medical Association; 2008.
- Patel AK, Fonseca V. Turning glucosuria into a therapy: efficacy and safety with SGLT2 inhibitors. Curr Diabetes Rep. 2010;10:101–107.
- Ehrenkranz JRL, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–38.
- Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323–330.
- Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol. 2010;50:623–635.
- Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875–883.
- Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010;50:636–646.
- Weight loss in obese subjects taking either GW869682 or placebo 3 times per day for 12 weeks [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00297180
- Sergliflozin [cited 2015 Dec 18]. Available from: http://adisinsight.springer.com/drugs/800018020
- Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35:2198–2200.
- Kapur A, O’Connor-Semmes R, Hussey EK, et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM). Diabetes. 2009;58(Suppl 1):A136.
- Dobbins RL, O’Connor-Semmes R, Kapur A, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab. 2012;14:15–22.
- Hussey EK, Kapur A, O’Connor-Semmes R, et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol. 2013;14:25.
- Sykes AP, Kemp GL, Dobbins R, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17:98–101.
- Sykes AP, O’Connor-Semmes R, Dobbins R, et al. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17:94–97.
- Islet Sciences, Inc. Presents positive clinical results for best-in-class SGLT2 inhibitor at American Diabetes Association (ADA) annual meeting [cited 2015 Dec 18]. Available from: http://www.prnewswire.com/news-releases/islet-sciences-inc-presents-positive-clinical-results-for-best-in-class-sglt2-inhibitor-at-american-diabetes-association-ada-annual-meeting-263266861.html
- Safety and efficacy of biphasic remogliflozin etabonate in the treatment of type 2 diabetes [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02537470
- Investigation of weight loss and body composition changes after dosing with either placebo or one of two active drugs [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT00494767
- Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem. 2009;52:1785–1794.
- Clinical studies with SGLT2 inhibitors [cited 2015 Dec 18]. Available from: https://books.google.gr/books?id=0rmlVGhlJ0IC&pg=PA73&lpg=PA73&dq=sergliflozin+phase+2&source=bl&ots=toqL5x2tmG&sig=gvfyPdrw9pZQ7TWMUSTQFFH0Q_E&hl=el&sa=X&ved=0CD0Q6AEwBGoVChMIubnM0JLeyAIVR-wUCh21qQFf#v=onepage&q=sergliflozin%20phase%202&f=false
- Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
- Yao CH, Song JS, Chen CT, et al. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem. 2011;54:166–178.
- Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl. 2011;120:S14–S19.
- Haas B, Eckstein N, Pfeifer V, et al. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014;4:e143.
- AstraZeneca (2014a) Xigduo™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes [cited 2015 Dec 18]. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20142101–xigduo-dapagliflozin-and-metformin-hydrochloride
- Background document. Dapagliflozin. Bms-512148. Nda 202293. Us food & drug administration (FDA). Endocrinologic & metabolic drug advisory committee (EMDAC) [cited 2015 Dec 18]. Available from: http://www.fda.gov/downloads/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf
- Bristol-Myers Squibb Company. Forxiga [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2014.
- Center for Drug Evaluation and Research. Application number: 202293orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s) [cited 2015 Dec 18]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293orig1s000clinpharmr.pdf
- Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2012;46:590–598.
- Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
- Anonymous. Dapagliflozin: BMS 512148; BMS-512148. Drugs R D. 2010;10:47–54.
- Carlson GF, Tou CKP, Parikh S, et al. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther. 2011;2:123–132.
- Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76:432–444.
- Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
- Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:357–365.
- Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13:47–54.
- Imamura A, Kusunoki M, Ueda S, et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther. 2013;4:41–49.
- Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29:163–177.
- Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17–27.
- Study to evaluate the potential pharmacokinetic interaction and pharmacodynamic effects on renal parameters of bumetanide (1mg) and dapagliflozin (10 mg) when co-administered in healthy subjects [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT00930865
- Kasichayanula S, Liu X, Griffen SC, et al. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab. 2013;15:280–283.
- List JF, Woo VC, Villegas EM, et al. Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes. Diabetes. 2008;57(Suppl.1):94.
- Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432–440.
- Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
- Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74:2191–2209.
- First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease [cited 2015 Dec 18]. Available from: http://www.investor.jnj.com/releasedetail.cfm?releaseid=710584
- Canagliflozin. Summary of product characteristics [cited 2015 Dec 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf
- Center for Drug Evaluation and Research. Application number: 204042orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s) [cited 2015 Dec 18]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf
- Canagliflozin as an adjunctive treatment to diet and exercise alone or co- administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus [cited 2015 Dec 18]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf
- Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–1238.
- Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–1145.
- A study of the safety and effectiveness of canagliflozin (JNJ-28431754) in promoting weight loss in overweight and obese patients who do not have diabetes [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00650806?sect=X70156&term=canagliflozin+AND+phase+2&rank=6#outcome1
- Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90.
- JARDIANCE® (empagliflozin) tablets, for oral use initial U.S. approval. 2014 [cited 2015 Dec 18]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
- Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152–161.
- Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213–219.
- Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:132–140.
- Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29:889–899.
- Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33–42.
- Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013;15:316–323.
- Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35:226–235.
- Giessmann T, Heise T, Macha S, et al. Lack of interaction between the sodium glucose co-transporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM. Diabetes. 2012;61:A614.
- Macha S, Lang B, Pinnetti S, et al. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers. Clin Pharmacol Drug Dev. 2012;1:181.
- Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721–728.
- Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31:621–638.
- Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther. 2015;32:306–318.
- Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
- Rosenstock J, Jelaska A, Wang F, et al. Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes mellitus. Diabetologia. 2013;56:S372.
- Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014;3:212262.
- Hedrington MS, Davis SN. The role of empagliflozin in the management of type 2 diabetes by patient profile. Ther Clin Risk Manag. 2015;11:739–749.
- Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs. 2014;74(5):611–617.
- Launch of Suglat® tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes, first SGLT2 inhibitor in Japan, providing new options in the treatment of type 2 diabetes [cited 2015 Dec 18]. Available from: http://www.astellas.com/en/corporate/news/detail/launch-of-suglat-tablets-a-sel.html
- Veltkamp SA, Kadokura T, Krauwinkel WJJ, et al. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31:839–851.
- Veltkamp SA, van Dijk J, Collins C, et al. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012;34:1761–1771.
- Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14:937–943.
- Ferrannini E, Veltkamp SA, Smulders RA, et al. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013;36:1260–1265.
- Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:268–273.
- Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219–1227.
- Wilding JP, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15:403–409.
- Filing for marketing approval of SGLT2 inhibitor luseogliflozin hydrate (TS-071) in Japan [cited 2015 Dec 18]. Available from: http://www.taishoholdings.co.jp/en/release/2013/2013041801-e.pdf
- Sasaki T, Seino Y, Fukatsu A, et al. Absence of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and various oral antidiabetic drugs in healthy Japanese males. Adv Ther. 2015;32:404–417.
- Sasaki T, Seino Y, Fukatsu A, et al. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2014;31:345–361.
- Sasaki T, Seino Y, Fukatsu A, et al. Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2015;32:319–340.
- Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30:1219–1230.
- Seino Y, Sasaki T, Fukatsu A, et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30:1231–1244.
- Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15:2741–2749.
- Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs. 2014;74:945–950.
- Chugai pharmaceutical: development pipeline [cited 2015 Dec 18]. Available from: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html
- Tofogliflozin [cited 2015 Dec 18]. Available from: http://adisinsight.springer.com/drugs/800027532
- Zell M, Husser C, Kuhlmann O, et al. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica. 2014;44:369–378.
- Rosenwasser RF, Rosenwasser JN, Sutton D, et al. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2014;50:739–745.
- Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
- Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:984–993.
- Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749–766.
- Kasahara N, Fukase H, Ohba Y, et al. A pharmacokinetic/pharmacodynamic drug-drug interaction study of tofogliflozin (a new SGLT2 inhibitor) and selected anti-type 2 diabetes mellitus drugs. Drug Res (Stuttg). 2015. [Epub ahead of print].
- Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2015. [Epub ahead of print].
- Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246–255.
- Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90–100.
- Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to develop and commercialize ertugliflozin, an investigational medicine for type 2 diabetes [cited 2015 Dec 18]. Available from; http://www.mercknewsroom.com/press-release/research-and-development-news/merck-co-inc-and-pfizer-enter-worldwide-collaboration-ag
- Gliflozin [cited 2015 Dec 18]. Available from: https://en.wikipedia.org/wiki/Gliflozin
- A single escalating dose study of ertugliflozin (PF-04971729, MK-8835) under fed and fasted conditons in healthy volunteers (MK-8835-036) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT00989079?term=ertugliflozin+phase+2&rank=10
- A phase 1 study of ertugliflozin in healthy male participants (MK-8835-020) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02411929?term=ertugliflozin+phase+2&rank=7
- Effects of ertugliflozin (PF-04971729, MK-8835) in participants with type 2 diabetes (MK-8835-040) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT01054300?term=ertugliflozin+phase+2&rank=6
- Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591–598.
- Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805–808.
- Safety and efficacy of ertugliflozin in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin (MK-8835-006) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02036515?term=ertugliflozin+phase+2&rank=13
- Efficacy and safety of ertugliflozin (MK-8835/PF-04971729) with sitagliptin in the treatment of participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise (MK-8835-017) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02226003?term=ertugliflozin+phase+2&rank=8
- A study of the efficacy and safety of ertugliflozin in participants with type 2 diabetes mellitus with stage 3 chronic kidney disease who have inadequate glycemic control on antihyperglycemic therapy (MK-8835-001) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT01986855?term=ertugliflozin+phase+2&rank=5
- Sotagliflozin (LX4211) [cited 2015 Dec 18]. Available from: http://www.lexpharma.com/pipeline/lx4211.html
- Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65:317–327.
- Freiman J, Ye G, Ogbaa I, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, shows a favorable gastrointestinal and genitourinary safety profile in type 2 diabetes mellitus (T2DM) patients and healthy subjects. Abstract presented at: 72nd Annual Meeting of the American Diabetes Association; 2012 Jun 8–12; Philadelphia, PA. Presentation 773.
- Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250–259.
- Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158–169.
- Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35:273–285.
- LX4211, a dual inhibitor of SGLT2 and SGLT1, shows rapid and significant improvement in glycemic control over 4 weeks in patients with type 2 diabetes mellitus [cited 2015 Dec 18]. Available from: http://www.lexicon-genetics.com/~lexpha5/images/pdfs/LX4211_ENDO2010_Presentation.pdf
- Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38:431–438.
- Lapuerta P, Rosenstock J, Zambrowicz B, et al. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy. Clin Cardiol. 2013;36:367–371.
- Efficacy and safety of sotagliflozin in young adult patients with type 1 diabetes mellitus and elevated hemoglobin A1C [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02383940
- Efficacy, safety, and tolerability study of sotagliflozin as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy (inTandem1) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02384941
- Efficacy, safety, and tolerability study of sotagliflozin as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy (inTandem2) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02421510
- A phase 3 study to evaluate the safety of sotagliflozin in patients with type 1 diabetes who have inadaquate glycemic control with insulin therapy alone (inTandem3) [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531035
- A study to compare the pharmacodynamics of canagliflozin and dapagliflozin in healthy volunteers [cited 2015 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01877889
- Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61:2199–2204.
- Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62:3324–3328.
- Nagata T, Suzuki M, Fukazawa M, et al. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys. Am J Physiol Renal Physiol. 2014;306:F1520–F1533.
- Kashiwagi A, Kazuta K, Yoshida S, et al. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2014;5:382–391.
- Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453–1469.
- Bolinder J, Ö L, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
- Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol. 2003;40 Suppl 1:S302–S304.
- Ohkura T. Ipragliflozin: a novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes. 2015;6:136–144.
- FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [cited 2015 Mar 17]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
- Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
- Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
- SGLT2 inhibitors (Gliflozins) [cited 2015 Mar 17]. Available from: http://www.diabetes.co.uk/diabetes-medication/sglt2-inhibitors.html
- Experts conclude that risk-benefit ratio overwhelmingly favors continued use of SGLT-2 [cited 2015 Mar 17]. Available from: http://www.diabetesincontrol.com/use-sglt-2-inhibitors/
- FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density [cited 2015 Jun 1]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm
- Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157–166.
- Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101:44–51.
- Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
- Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
- Summary of the risk management plan (RMP) for Jardiance (empagliflozin) [cited 2015 Jun 1]. Available from: https://www.fimea.fi/documents/542809/835259/27456_Jardiance_RMP_summary-EN.pdf
- Hinnen D. Short commentary on empagliflozin and its potential clinical impact. Ther Adv Endocrinol Metab. 2015;6:68–81.